Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > 52 week low

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Jul 17, 2021 7:54pm

150 Views

Post# 33565802

RE:RE:RE:RE:RE:52 week low

Doccole wrote:
I am going to be logging in tonight and I will be voting. I am with you, and I'm not happy with the way this has played out. You detailed it pretty well.

This is our chance as retail to show we are not happy, even if the likelyhood of change isn't likely.

If the likelihood isn't likely ... then what are you saying?
What you're saying is that you don't like him but that you're in the minority.
I believe you are correct in that, if that's what you're saying, but we'll have to wait for the voting to know for sure.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario